



Synthesis, characterization and biological assay of Organotin derivatives of Sulphanilamide

Khan MA¹, Akhtar S¹, Shahid K¹

¹Riphah Institute of Pharmaceutical Sciences, Riphah International University, 7th Avenue, Sector G-7/4, Islamabad, 44000, Pakistan

Address for Correspondence
Mohsin Abbas Khan
E-mail : lasharibloch@hotmail.com

Received: 20-06-2014
Review completed: 04-07-2014
Accepted: 07-07-2014

Access this article online

QR Code



Website:
www.ijrpsonline.com

ABSTRACT

Metals and its compound had played a major role as therapeutic agents in history of medicine and in modern pharmacology as well. A family of Organotin complexes (Sn¹ - Sn⁶) of sulphanilamide were synthesized by the reaction of triorganotin or diorganotin chloride with the sulphanilamide by adding triethylamine in dry toluene. All the synthesized Complexes were characterized by combination of different techniques using Fourier Transform-Infrared spectroscopy, ¹H and ¹³C Nuclear magnetic resonance spectroscopy and elemental analysis. *In-vitro* antibacterial and antifungal activities were investigated. Biological screening showed that most of the derived complexes have significant activity against different tested pathogenic strains of bacteria and fungi.

Key words: Sulphanilamide, Organotin, FT-IR, *In-vitro* Biological assay

INTRODUCTION

Organotin compounds have several applications in many fields from many years. Organotin(IV) complexes have been the subject of interest from the last few decades because of their biomedical and commercial applications¹. It has been observed that several organotin complexes are effective antifouling, antimicrobial², and antiviral agents. The interesting application of metal complexes in the treatment of numerous human diseases is a vigorously expanding area in biomedical and inorganic chemistry³. The variation in coordination number, geometries, accessible redox states, thermodynamic, and kinetic characteristics and the intrinsic properties of the metal ion are some special characteristics of organometallic complexes that offer the medicinal chemists to employ different strategies for their exploitation⁴. Their use in cancer chemotherapy is gaining mounting importance after the discovery of metal based drug Cisplatin⁵. Sulphanilamide is a potent organic antibacterial agent consisting of an aniline derivitized with a sulphonamide group. Sulphanilamide competitively inhibits enzymatic reactions involving para-amino benzoic acid (PABA)⁶. PABA is involved in enzymatic reactions

that produce folic acid which acts as a coenzyme in the synthesis of purine, pyrimidine and other amino acids. Sulphanilamide was used in World War 2 as a first-aid treatment to reduce infection rates and contributed to a dramatic reduction in mortality rates compared to previous wars^{7,8}. Modern antibiotics have supplanted sulfanilamide on the battlefield; however, sulfanilamide remains in use for treatment of vaginal yeast infections⁹. Present study involves the synthesis, spectroscopic characterization, elemental analysis and biological screening of the newly synthesized organotin complexes of sulphanilamide.

MATERIALS AND METHODS

All the chemicals, metal salts, reagents were purchased from Sigma Aldrich laboratories and were used as purchased except toluene which was dried by using sodium wire prior to use. All the glassware were properly dried at 120°C. Synthesis was done at Riphah Institute of Pharmaceutical Sciences. Biological screening was done at Quaid-e-Azam University Pakistan. Spectroscopic characterization was done at Institute of Pharmaceutical Sciences, Kings College London.

General Procedure for the Synthesis of Organotin Derivatives of Sulphanilamide

Sulphanilamide was suspended in dry toluene (50 ml) and treated with triethylamine Et_3N . The mixture was refluxed for 3 hours. To a solution triorganotin chloride or Diorganotin dichloride was added as solid to a reaction flask with constant stirring and the reaction mixture refluxed 3 hours. The reaction mixture contains Et_3NHCl is filtered off such that filtrate had the organotin derivative. The solvent is removed through rotary apparatus. The mass left behind will be recrystallization from CHCl_3 ¹⁰⁻¹⁴ [9-13].




Figure 1: Scheme for Synthesis of Organotin Derivatives.

The physicochemical properties of the synthesized organotin metal complexes are described below

Sn (Sulphanilamide)

White powder, m. p. 165°C , FT-IR (cm^{-1}) 3476s, 3372s, 3264s $\nu(\text{NH})$, 1593 $\nu(\text{CH}=\text{CH})$, 1143 $\nu(\text{C}-\text{N})$, 1303 $\nu(\text{S}=\text{O})$ ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.43-7.46d; 6.56-6.0d ($-\text{C}_6\text{H}_4-$), 6.9s ($-\text{NH}_2$), 5.81s ($\text{H}_2\text{N}-\text{SO}_2$), ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 152.38 (C-1), 112.88 (C-2/6), 127.88 (C-3/5), 130.45 (C-4).

Sn^1 (Triphenyltin derivative of sulphanilamide) [(Ph₃Sn)₂-sulphanilamide]

Yield (81%), m. p. 150°C , Elemental Analysis: calculated for $\text{C}_{42}\text{H}_{36}\text{N}_2\text{O}_2\text{SSn}_2$: C, 57.97; H, 4.17; N, 3.22; found: C, 58.13; H, 3.99; N, 3.35; FT-IR (cm^{-1}) 3373s $\nu(\text{NH})$, 3067 $\nu(\text{CH})$, 1594 $\nu(\text{CH}=\text{CH})$, 1145 $\nu(\text{C}-\text{N})$, 1304 $\nu(\text{S}=\text{O})$, 438

$\nu(\text{Sn}-\text{N})$, ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.83-7.84d; 6.57-6.59d; ($-\text{C}_6\text{H}_4-$), 7.41-7.45m; ($-\text{C}_6\text{H}_5$), 6.89s ($-\text{NH}-$), 5.81s ($-\text{NHSO}_2$) ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 151.89 (C-1), 112.38 (C-2/6), 128.37 (C-3/5), 129.0 (C-4), 129.97 (C-7), 136.19 (C-8/12), 128.03 (C-9/11), 127.38 (C-10).

Sn^2 (Diphenyltin derivative of sulphanilamide) [(Ph₂Sn)₂-sulphanilamide]

Yield (73%), semisolid, Elemental Analysis: calculated for $\text{C}_{36}\text{H}_{32}\text{N}_4\text{O}_4\text{S}_2\text{Sn}_2$: C, 48.79; H, 3.64; N, 6.32; found: C, 48.68; H, 3.71; N, 6.22; FT-IR (cm^{-1}) 3369s $\nu(\text{NH})$, 3069 $\nu(\text{CH})$, 1595 $\nu(\text{CH}=\text{CH})$, 1147 $\nu(\text{C}-\text{N})$, 1310 $\nu(\text{S}=\text{O})$, 452 $\nu(\text{Sn}-\text{N})$, ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.91-7.95d; 6.55-6.57d ($-\text{C}_6\text{H}_4-$), 6.88s ($-\text{NH}-$), 6.80s ($-\text{NH}-\text{SO}_2$), 7.42m, 7.44m; ($-\text{C}_6\text{H}_5$), ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 151.9 (C-1), 112.37 (C-2/6), 134.75 (C-3/5), 129.94 (C-4), 127.06 (C-7), 136.33 (C-8/12), 127.75 (C-9/11), 127.38 (C-10).

Sn^3 (Tributyltin derivative of sulphanilamide) [(Bu₃Sn)₂-sulphanilamide]

Yield (65%), m. p. 180°C , Elemental Analysis: calculated for $\text{C}_{30}\text{H}_{60}\text{N}_2\text{O}_2\text{SSn}_2$: C, 48.02; H, 8.06; N, 3.73; found: C, 47.95; H, 8.15; N, 3.61; FT-IR (cm^{-1}) 3372s $\nu(\text{NH})$, 2956 $\nu(\text{CH})$, 1594 $\nu(\text{CH}=\text{CH})$, 1144 $\nu(\text{C}-\text{N})$, 1304 $\nu(\text{S}=\text{O})$, 477 $\nu(\text{Sn}-\text{N})$, ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.45-7.47d; 6.58-6.60d; ($-\text{C}_6\text{H}_4-$), 6.90s ($-\text{NH}-$), 5.82s ($-\text{NH}-\text{SO}_2$), 0.90d (CH_3-), 1.31-1.63m; ($-\text{CH}_2-\text{CH}_2-$), 1.29m; ($\text{Sn}-\text{CH}_2$) ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 151.88 (C-1), 112.37 (C-2/6), 129.96 (C-3/5), 127.38 (C-4), 13.62 (C-7), 26.22 (C-8), 27.71 (C-9), 21.02 (C-10).

Sn^4 (Dibutyltin derivative of sulphanilamide) [(Bu₂Sn)₂-sulphanilamide]

Yield (59%), semisolid, Elemental Analysis: calculated for $\text{C}_{28}\text{H}_{48}\text{N}_4\text{O}_4\text{S}_2\text{Sn}_2$: C, 41.71; H, 6.00; N, 6.95; found: C, 41.85; H, 5.87; N, 7.11; FT-IR (cm^{-1}) 3372s $\nu(\text{NH})$, 2959 $\nu(\text{CH})$, 1596 $\nu(\text{CH}=\text{CH})$, 1148 $\nu(\text{C}-\text{N})$, 1338 $\nu(\text{S}=\text{O})$, 411 $\nu(\text{Sn}-\text{N})$, ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.42-7.47d; 6.56-6.11d; ($-\text{C}_6\text{H}_4-$), 6.88s; ($-\text{NH}-$), 5.80s; ($-\text{NH}-\text{SO}_2$), 0.87-0.88m; (CH_3-), 1.65m; ($-\text{CH}_2-\text{CH}_2-$) 1.16-1.29m; ($-\text{CH}_2-$), ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 152.02 (C-1), 112.35 (C-2/6), 129.94 (C-3/5), 127.36 (C-4), 8.68 (C-7), 27.31 (C-8), 25.65 (C-9), 13.48 (C-10).

Sn^5 (Trimethyltin derivative of sulphanilamide) [(Me₃Sn)₂-sulphanilamide]

Yield (67%), m. p. 155°C , Elemental Analysis: calculated for $\text{C}_{12}\text{H}_{24}\text{N}_2\text{O}_2\text{SSn}_2$: C, 28.95; H, 4.86; N, 5.63; found: C, 29.09; H, 5.00; N, 5.42; FT-IR (cm^{-1}) 3373s $\nu(\text{NH})$, 2958 $\nu(\text{CH})$, 1595 $\nu(\text{CH}=\text{CH})$, 1146 $\nu(\text{C}-\text{N})$, 1311 $\nu(\text{S}=\text{O})$, 411 $\nu(\text{Sn}-\text{N})$, ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.45-7.48d; 6.59-6.61d; ($-\text{C}_6\text{H}_4-$), 6.92s ($-\text{NH}-$), 5.83s ($-\text{NH}-\text{SO}_2$), 0.87s (CH_3-) ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 151.88 (C-1), 112.4 (C-2/6), 129.96 (C-3/5), 127.39 (C-4), 5.2 (C-7).

Sn^6 (Dimethyltin derivative of sulphanilamide) [(Me₂Sn)₂-sulphanilamide]

Yield (55%), m. p. 140°C , Elemental Analysis: calculated for $\text{C}_{16}\text{H}_{24}\text{N}_4\text{O}_4\text{S}_2\text{Sn}_2$: C, 30.12; H, 3.79; N, 8.78; found: C, 29.98; H, 3.68; N, 8.87; FT-IR (cm^{-1}) 3344s

$\nu(\text{NH})$, 3066, 2984 $\nu(\text{CH})$, 1593 $\nu(\text{CH}=\text{CH})$, 1144 $\nu(\text{C}-\text{N})$, 1335 $\nu(\text{S}=\text{O})$, 447 $\nu(\text{Sn}-\text{N})$, ^1H NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 7.44-7.46d; 6.58-6.60d; ($-\text{C}_6\text{H}_4-$), 6.9s ($-\text{NH}-$), 5.83s ($-\text{NH}-\text{SO}_2$), 1.17s (CH_3-), ^{13}C NMR ($\text{DMSO}_4\text{-D}_6$, ppm), 151.89 (C-1), 112.38 (C-2/6), 129.93 (C-3/5), 127.37 (C-4), 8.69 (C-7).

Antibacterial activity

The antibacterial activity of organotin derivatives of sulphanilamide was tested against *Escherichia coli* (Gram-negative) and *Staphylococcus aureus* (Gram-positive) using the agar well diffusion method^{15,16}. Cefixime and DMSO were used as positive and negative controls respectively. The wells were dug in the media by using a sterile metallic borer with the centre at least 24 mm apart. The recommended concentration of the test sample (2 mg/ml in DMSO) was introduced into the respective wells. Other wells were supplemented with DMSO and reference antibacterial drugs serving as negative and positive controls, respectively. The plates were incubated immediately at 37 °C for 20 h. The activity was determined by measuring the diameter of zones showing complete inhibition in millimetres. Growth inhibition was calculated with reference to positive control.

Antifungal activity

The antifungal activity of synthesized organotin derivatives of sulphanilamide were tested against *Aspergillus Flavus*, *Aspergillus Niger*, *Rhizoctonia Solani*, *Aspergillus Fumigatus* and *Mucor* by using the tube diffusion test^{17,18}. Terbinafine (200 mg/ml) was used as standard drug, positive control and DMSO as negative control. The amount of growth inhibition was calculated as:

$$\text{Inhibition (\%)} = [(A-B)/B] \times 100$$

A = Diameter of fungal colony in control plate

B = Diameter of fungal colony in test plate

RESULTS AND DISCUSSION

The organotin derivatives of sulphanilamide were mostly solid except diphenyltin and dibutyltin these were semisolid and all derivatives were physically stable. FT-IR spectra rang 4000-400 cm^{-1} were measure and the three sharps peaks of NH_2 , and NH_2-SO_2 between the range of 3350 and 3250 cm^{-1} (stretching) become single peak around 3300-3400 cm^{-1} symmetric The peak of CH aliphatic 2850-2960 cm^{-1} (stretching sp^3) and CH aromatic at 3000 cm^{-1} (stretching sp^2) appeared and were more profound in butyltin, methyltin and phenyltin derivatives respectively. ^1H NMR and ^{13}C NMR shows the no. of proton and carbon according to structure in the expected ranges. Elemental analysis also corresponds well with the calculated values. Antibacterial and antifungal activities were done and the results showed that sulphanilamide were inactive against the microbes but interestingly the synthesized organotin derivatives were active to some extent. The highest activity was exhibited by Sn^3 (Tributyltin derivative of sulphanilamide) [$(\text{Bu}_3\text{Sn})_2$ -sulphanilamide] against the pathogenic bacterial as well as fungal strains. The results of the biological screening are given below in table 1 and

table 2, whereas in figure 1 and figure 2 graphical illustrations of the results are shown.

Table 1: Antibacterial activity of Organotin Derivatives of Sulphanilamide

Samples	<i>Staph. Aureus</i>	<i>E.coli</i>
Sulphanilamide	0	0
Sn^1	14	0
Sn^2	7	0
Sn^3	30	30
Sn^4	8	0
Sn^5	15	16
Sn^6	10	0
Cefixime	21	21
DMSO	0	0




Figure 2: Graph representing Antibacterial activity of Organotin Derivatives of Sulphanilamide

Table 2. Antifungal activity of the organotin derivatives of Sulphanilamide

Sample	<i>A. Flavous</i>	<i>A. Niger</i>	<i>A. Solani</i>	<i>A. Fumigatus</i>	Mucor SP
Sulphanilamide	0	0	0	0	15
Sn^1	11	14	15	19	18
Sn^2	11	14	15	20	17
Sn^3	26	25	14	29	15
Sn^4	0	0	0	0	0
Sn^5	0	0	6	0	0
Sn^6	0	0	0	0	0
Terbinafine	28	33	35	30	33
DMSO	0	0	0	0	0




Figure 3: Graph Representing Antifungal activity of the organotin derivatives of Sulphanilamide.

CONCLUSION

Organotin derivatives of sulphanilamide were synthesized in appreciable yield and characterized spectroscopically. Newly synthesized Organotin derivatives of sulphanilamide were observed to be more active than their parent drug sulphanilamide against bacterial and fungal strains. Hence we conclude that metal complexation enhances the pharmacological potential of the drug.

AKNOWLEDGEMENT

We are thankful to Higher Education Commission of Pakistan, for their financial support and Dr. IhsanUIHaq, lecturer, department of pharmacy, Quaid-e-Azam university Islamabad for assisting in biological screening.

REFERENCE

- Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. *Expert Opinion on Therapeutic Patents*. 2000;10(5):575-600.
- Ogden RC, Flexner CW. *Protease inhibitors in AIDS therapy*: Marcel Dekker New York, USA; 2001.
- Supuran CT, Scozzafava A, Mastrolorenzo A. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. *Expert Opinion on Therapeutic Patents*. 2001;11(2):221-259.
- Kumar S, Dhar DN, Saxena P. Applications of metal complexes of Schiff bases—a review. *Journal of scientific and industrial research*. 2009;68(3):181-187.
- Dabrowiak JC. *Metals in medicine*: John Wiley & Sons; 2009.
- Kent M. *Advanced biology*: Oxford University Press; 2000.
- Coburn AF, Young DC. *The Epidemiology of Hemolytic Streptococcus during World War II in the United States Navy. The Epidemiology of Hemolytic Streptococcus during World War II in the United States Navy*. 1949.
- Lesch JE. *The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine*: Oxford University Press; 2007.
- Harris GH. *Heterocyclic Analogues of Sulphanilamide*: Stanford University; 1939.
- Shahid K, Ali S, Shahzadi S. The chemistry, properties, and characterization of organotin (IV) complexes of 2-(N-naphthylamido) benzoic acid. *Journal of Coordination Chemistry*. 2009;62(17):2919-2926.
- Shahid K, Shahzadi S, Ali S. Spectroscopic studies of biologically active organotin (IV) derivatives of 2-[N-(2, 4, 6-tribromophenylamido) propanoic acid. *JICS*. 2008;5(4):579-587.
- Shahzadi S, Shahid K, Ali S, Bakhtiar M. Characterization and Antimicrobial Activity of Organotin (IV) Complexes of 2-[(2', 6'-diethylphenylamido)] benzoates and 3-[(2', 6'-

- diethylphenylamido)] propanoates. *Turkish Journal of Chemistry*. 2008;32(3):333.
- Ahmad MS, Hussain M, Hanif M, Ali S, Qayyum M, Mirza B. Di-and Triorganotin (IV) Esters of 3, 4-Methylenedioxyphenylpropenoic Acid: Synthesis, Spectroscopic Characterization and Biological Screening for Antimicrobial, Cytotoxic and Antitumor Activities. *Chemical biology & drug design*. 2008;71(6):568-576.
- Hanif M, Hussain M, Ali S, Bhatti MH, Ahmed MS, Mirza B, Evans HS. Synthesis, spectroscopic investigation, crystal structure, and biological screening, including antitumor activity, of organotin (IV) derivatives of piperonylic acid. *Turkish Journal of Chemistry*. 2007;31(3):349-361.
- Atta-ur-Rahman, Choudhary MI, Thomsen WJ. *Bioassay techniques for drug development*: Harwood academic publishers The Netherlands; 2001.
- Blank H, Rewbell G. *Arch Derm*. 92 (1965) 319; b) SS Shaukat, NA Khan, F. Ahmed. *Pak J Bot*. 1980;12:97.
- Masood H, Ali S, Mazhar M, Shahzadi S, Shahid K. ¹H, ¹³C, ¹¹⁹Sn NMR, Mass, Moss auer and Biological Studies of Tri-, Di-and Chlorodiorganotin (IV) Car oxylates. *Turkish Journal of Chemistry*. 2004;28(1).
- Armarego WL, Chai C. *Purification of laboratory chemicals*: Butterworth-Heinemann; 2012.